NOTE H — PATENTS

	December 31, 2019
	Cost		Impairment			Accumulated Amortization			Net
Patents-foundation intellectual property	$	1,377,863	$	-		$	(995,603	)	$	382,260
Total	$	1,377,863	$	-		$	(995,603	)	$	382,260
	December 31, 2018
	Cost		Impairment			Accumulated Amortization			Net
Patents-foundation intellectual property	$	1,377,863	$	-		$	(942,590	)	$	435,273
Epidural-Apad acquired patents		2,639,647		(1,539,794	)		(1,099,853	)		-
Total	$	4,017,510	$	(1,539,794	)	$	(2,042,443	)	$	435,273

Patents are amortized utilizing the straight-line method over estimated useful lives ranging from

years. Amortization expense was

$53,013

and

$814,681

for the year ended

December 31, 2019

and

2018,

respectively. The annual amortization expense expected to be recorded for existing intangibles assets for the years

2020

through

2024

is approximately

$53,000,

$47,000

and

$33,000.

July 13, 2017,

Milestone Scientific consummated an Asset Purchase Agreement (the “Agreement”) with APAD Octrooi B.V. and APAD B.V. (each, a “Seller” and collectively, the “Sellers”) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers’ computer-controlled injection instrument (the “Purchased Assets”) accounted for as an asset acquisition. The patents purchased in the amount of approximately

$2,639,000

were capitalized and were expected to be amortized over their

three

-year estimated useful life.

During

2018,

the Company determined that the APAD Patents will

not

be further developed or commercialized before their estimated useful life expires. As such, Management determined that these assets were impaired and a charge of approximately

$1.5

million was recorded.